Key facts
- This page summarizes Thomas A. Fitzgerald's Form 4 filing for Transcode Therapeutics, Inc. (RNAZ).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 11 Sep 2026, 17:10.
Thomas A. Fitzgerald - 09 Sep 2026 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)
- Reporting relationship
- Chief Financial Officer, Director
- Issuer ticker
- RNAZ
- Reported as of
- 09 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Sep 2026, 17:10:20 UTC
- Prior SEC filing
- 18 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas A. Fitzgerald
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Thomas A. Fitzgerald filed Form 4 for Transcode Therapeutics, Inc. (RNAZ) on 11 Sep 2026.
Change
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001854168
Primary reporting owner
Fitzgerald Thomas A
- Relationship
- Chief Financial Officer, Director
- Address
- C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON
- Signature
- /s/ Thomas A. Fitzgerald
- Signature date
- 11 Sep 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RNAZ
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +185,000
- Change %
- Price
- $0.000000*
- Shares after
- 185,000
- Date
- 09 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 185,000
- Exercise price
- $1.78
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Thomas A. Fitzgerald is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
The shares underlying this option shall vest and become exercisable in twelve (12) equal monthly installments following the grant date.